Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Cell to Cure ApS
APS
Active
Advertising protection
CVR 39401975
Kajerødgård 9, 3460
Birkerød
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 8 years old
14 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Cell to Cure ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (4)
MR
Martin Roland Jensen
Management
Management
2022
MH
Mandana Haack-Sørensen
Management
Management
2018
JK
Jens Kastrup
Chief Executive Officer
Chief Executive Officer
2018
AE
Annette Ekblond
Management
Management
2018
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
AØ
Anders Østergaard
Chairman
Chairman
2024
Former (1)
JK
Jesper Kihl
Board of Directors
Board of Directors
2022 – 2024
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Endeavour Cells ApS
Company
50–66.65%
50–66.65%
2024
JKastrup.ApS
Company
10–14.99%
10–14.99%
2024
Ekblond.ApS
Company
10–14.99%
10–14.99%
2024
LMN.ApS
Company
10–14.99%
10–14.99%
2024
MEDIC ADVICE ApS
Company
5–9.99%
5–9.99%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Cell to Cure ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
